trial
as of 2026-07-01Treatment of MDEs During the Course of Psychotic Disorders With Duloxetine
NCTId NCT00224302
at a glance
Phase 4 · Completed
Enrollment 20 (estimated)
Sponsored by Central Institute of Mental Health, Mannheim
Primary completion 2007-11
Synthesized from structured facts only — each point cited above.
Design & status
Phase
Phase 4
Status
Completed
Enrollment
20 (estimated)
Study type
Interventional
Allocation
Non Randomized
Model
Single Group
Masking
None
Start
2005-08
Primary completion
2007-11
Eligibility
ALL · 18 Years · 65 Years
Interventions & indications
Drugs
Sponsors
Central Institute of Mental Health, MannheimLead Sponsor
Investigators
1
Mathias Zink, MDPrincipal Investigator
Sites
1 total
Mannheim, Germany
Facts & assertions
4 sourced
Enrollment
20
Phase
PHASE4
Primary Completion Date
2007-11
Status
COMPLETED
relationships
The graph out of here
drug
drug
lead_sponsor
indication
investigator
person